A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy.
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cyclophosphamide
/ therapeutic use
Disease-Free Survival
Doxorubicin
/ therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Prednisone
/ therapeutic use
Retrospective Studies
Rituximab
/ therapeutic use
Sweden
/ epidemiology
Vincristine
/ therapeutic use
DLBCL
elderly
first line therapy
real-world
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
26
5
2020
medline:
28
4
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
This real-world study investigated outcome of first-line treatment in elderly patients with diffuse large B-cell lymphoma (DLBCL). All (
Identifiants
pubmed: 32449636
doi: 10.1080/10428194.2020.1765233
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM